2022
Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus
Thomas A, Kereiakes D, Baumbach A, Windecker S, Pietras C, Dressler O, Issever M, Curtis M, Bertolet B, Zidar J, Smits P, Díaz V, McLaurin B, Cequier Á, Takahashi A, Cannon L, Amoroso G, Kakuta T, Saito S, Leon M, Lansky A. Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 1: 100033. PMID: 39132558, PMCID: PMC11307809, DOI: 10.1016/j.jscai.2022.100033.Peer-Reviewed Original ResearchTarget vessel myocardial infarctionVessel myocardial infarctionDiabetes mellitusDP-EESLesion failureIII trialsCardiac deathMyocardial infarctionBiodegradable Polymer Sirolimus-Eluting StentBiodegradable polymer sirolimus-eluting stentsTarget lesion failureTarget lesion revascularizationPercutaneous coronary interventionSirolimus-Eluting StentsLong-term inflammatory responseDiabetic subgroupsLesion revascularizationNondiabetic patientsSecondary endpointsBackground PatientsCoronary interventionPrespecified analysisComposite endpointPrimary safetyWorse outcomes
2013
A Blood-Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Nondiabetic Patients Referred for Myocardial Perfusion Imaging The COMPASS Study
Thomas GS, Voros S, McPherson JA, Lansky AJ, Winn ME, Bateman TM, Elashoff MR, Lieu HD, Johnson AM, Daniels SE, Ladapo JA, Phelps CE, Douglas PS, Rosenberg S. A Blood-Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Nondiabetic Patients Referred for Myocardial Perfusion Imaging The COMPASS Study. Circulation Genomic And Precision Medicine 2013, 6: 154-162. PMID: 23418288, DOI: 10.1161/circgenetics.112.964015.Peer-Reviewed Original ResearchConceptsMyocardial perfusion imagingInvasive coronary angiographyGene expression scoreCoronary angiographyNegative predictive valueNondiabetic patientsSymptomatic patientsClinical factorsPredictive valuePrespecified primary end pointObstructive coronary artery diseaseAbnormal myocardial perfusion imagingBlood-based gene expression testAdverse cardiovascular eventsPrimary end pointCoronary artery diseaseReceiver-operating characteristic curvePeripheral blood samplesReceiver-operating characteristic analysisCoronary artery disease diagnosisMaximum percent stenosisGene expression testReceiver-operating characteristicCardiovascular eventsArtery disease
2012
A gender-specific blood-based gene expression score for assessing obstructive coronary artery disease in nondiabetic patients: Results of the Personalized Risk Evaluation and Diagnosis in the Coronary Tree (PREDICT) Trial
Lansky A, Elashoff MR, Ng V, McPherson J, Lazar D, Kraus WE, Voros S, Schwartz RS, Topol EJ. A gender-specific blood-based gene expression score for assessing obstructive coronary artery disease in nondiabetic patients: Results of the Personalized Risk Evaluation and Diagnosis in the Coronary Tree (PREDICT) Trial. American Heart Journal 2012, 164: 320-326. PMID: 22980297, DOI: 10.1016/j.ahj.2012.05.012.Peer-Reviewed Original ResearchConceptsObstructive coronary artery diseaseCoronary artery diseaseMyocardial perfusion imagingGene expression scoreQuantitative coronary angiographyExpression scoreNondiabetic patientsArtery diseaseCardiac catheterizationCoronary angiographyBurden of CADSeverity of CADNoninvasive myocardial perfusion imagingProspective multicenter observational studyUnknown coronary artery diseaseSignificant coronary artery diseaseDiagnostic approachUnnecessary cardiac catheterizationMulticenter observational studyChest pain symptomsDiagnostic cardiac catheterizationAvailable noninvasive testsNoninvasive test resultsPositive predictive valueReliable diagnostic approachWhole Blood Gene Expression Testing for Coronary Artery Disease in Nondiabetic Patients: Major Adverse Cardiovascular Events and Interventions in the PREDICT Trial
Rosenberg S, Elashoff MR, Lieu HD, Brown BO, Kraus WE, Schwartz RS, Voros S, Ellis SG, Waksman R, McPherson JA, Lansky AJ, Topol EJ, for the PREDICT Investigators. Whole Blood Gene Expression Testing for Coronary Artery Disease in Nondiabetic Patients: Major Adverse Cardiovascular Events and Interventions in the PREDICT Trial. Journal Of Cardiovascular Translational Research 2012, 5: 366-374. PMID: 22396313, PMCID: PMC3349850, DOI: 10.1007/s12265-012-9353-z.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryCoronary AngiographyCoronary Artery BypassCoronary Artery DiseaseFemaleGene Expression RegulationGenetic Predisposition to DiseaseGenetic TestingHumansIschemic Attack, TransientLogistic ModelsMaleMiddle AgedMyocardial InfarctionOdds RatioPhenotypePredictive Value of TestsPrognosisProspective StudiesReproducibility of ResultsRisk AssessmentRisk FactorsStrokeTime FactorsUnited StatesConceptsMajor adverse cardiovascular eventsCoronary artery diseaseObstructive coronary artery diseaseGene expression scoreAdverse cardiovascular eventsCardiovascular eventsArtery diseaseClinical risk scoreGroup of patientsNegative predictive valueGene expression testingNondiabetic patientsPREDICT trialAngiography patientsGES groupPREDICT studyRisk scorePatientsPredictive valueExpression scoreRevascularizationEvent ratesDiseaseMonthsExpression testing
2011
Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Diabetic Patients With Acute Myocardial Infarction
Witzenbichler B, Wöhrle J, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Hood KL, Parise H, Lansky AJ, Nikolsky E, Mehran R, Stone GW. Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Diabetic Patients With Acute Myocardial Infarction. Circulation Cardiovascular Interventions 2011, 4: 130-138. PMID: 21364152, DOI: 10.1161/circinterventions.110.960245.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPaclitaxel-eluting stentsTarget lesion revascularizationBare metal stentsHORIZONS-AMI trialDiabetic patientsDiabetes mellitusStent thrombosisMyocardial infarctionPercutaneous interventionIschemia-driven target lesion revascularizationMetal stentsAcute Myocardial Infarction trialHigh-risk diabetic patientsMyocardial Infarction trialPrimary percutaneous interventionInsulin-treated diabetesAcute myocardial infarctionAngiographic late lossComparable safety outcomesBinary restenosisHarmonizing OutcomesLesion revascularizationNondiabetic patientsAngiographic restenosis
2010
Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients.
Rosenberg S, Elashoff MR, Beineke P, Daniels SE, Wingrove JA, Tingley WG, Sager PT, Sehnert AJ, Yau M, Kraus WE, Newby LK, Schwartz RS, Voros S, Ellis SG, Tahirkheli N, Waksman R, McPherson J, Lansky A, Winn ME, Schork NJ, Topol EJ. Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Annals Of Internal Medicine 2010, 153: 425-34. PMID: 20921541, PMCID: PMC3786733, DOI: 10.7326/0003-4819-153-7-201010050-00005.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overAlgorithmsArea Under CurveChest PainCoronary AngiographyCoronary Artery DiseaseDiabetes MellitusFemaleGene ExpressionHumansMaleMiddle AgedProspective StudiesReverse Transcriptase Polymerase Chain ReactionRisk AssessmentROC CurveSensitivity and SpecificitySex FactorsYoung AdultConceptsObstructive coronary artery diseaseCoronary artery diseaseCoronary angiographyNondiabetic patientsQuantitative coronary angiographyArtery diseasePresence of CADClinical modelMore major coronary arteriesPeripheral blood gene expressionBlood-based gene expression testDiamond-Forrester methodMulticenter prospective trialMajor coronary arteriesChronic inflammatory disordersIndependent validation cohortReceiver-operating characteristic analysisBlood gene expressionReal-time polymerase chain reactionWhole blood testCardiac protein markersGene expression testNoninvasive imaging methodProspective trialRisk patients
2007
Comparison of Myocardial Reperfusion in Patients Undergoing Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction With Versus Without Diabetes Mellitus (from the EMERALD Trial)
Marso SP, Miller T, Rutherford BD, Gibbons RJ, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Mehran R, Krucoff MW, Lansky AJ, Stone GW. Comparison of Myocardial Reperfusion in Patients Undergoing Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction With Versus Without Diabetes Mellitus (from the EMERALD Trial). The American Journal Of Cardiology 2007, 100: 206-210. PMID: 17631071, DOI: 10.1016/j.amjcard.2007.02.080.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionST-segment elevation myocardial infarctionElevation myocardial infarctionPrimary PCIMyocardial blush gradeCongestive heart failurePercutaneous coronary interventionMyocardial infarctionNondiabetic patientsDiabetes mellitusInfarct sizeMyocardial perfusionBlush gradeCoronary interventionHeart failureMyocardial reperfusionDiabetic patientsAcute ST-segment elevation myocardial infarctionST-segment elevation acute myocardial infarctionFinal myocardial blush gradeVersus Without Diabetes MellitusElevation acute myocardial infarctionSevere congestive heart failureDistal embolic protectionFinal infarct size
2005
Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial)
Stuckey TD, Stone GW, Cox DA, Tcheng JE, Garcia E, Carroll J, Guagliumi G, Rutherford BD, Griffin JJ, Turco M, Lansky AJ, Mehran R, Fahy M, Brodie BR, Grines CL, Investigators F. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). The American Journal Of Cardiology 2005, 95: 1-7. PMID: 15619385, DOI: 10.1016/j.amjcard.2004.08.054.Peer-Reviewed Original ResearchConceptsTarget vessel revascularizationAcute myocardial infarctionPrimary end pointDiabetic patientsNondiabetic patientsPrimary angioplastyDiabetes mellitusStent implantationMyocardial infarctionIschemic target vessel revascularizationEnd pointRoutine stent implantationAbciximab useComposite incidenceReperfusion modalityRoutine stentingAngiographic restenosisVessel revascularizationBalloon angioplastyImproved outcomesPatientsAngioplastyAbciximabDiabetesBeneficial effects
2003
Vascular brachytherapy using a beta emitter source in diabetic patients with in-stent restenosis: Angiographic and clinical outcomes
Suntharalingam M, Laskey WK, Tantibhedhyangkul W, Lansky A, Teirstein P, Bass T, Silber S, Rutherford B, Wilmer C, Popma JJ, Kuntz R, Bonan R. Vascular brachytherapy using a beta emitter source in diabetic patients with in-stent restenosis: Angiographic and clinical outcomes. International Journal Of Radiation Oncology • Biology • Physics 2003, 57: 536-542. PMID: 12957267, DOI: 10.1016/s0360-3016(03)00537-6.Peer-Reviewed Original ResearchConceptsVessel revascularization ratePercutaneous coronary interventionDiabetic patientsNondiabetic patientsVascular brachytherapyNondiabetic counterpartsStent restenosisRevascularization ratesCoronary interventionLess target lesion revascularizationConventional percutaneous coronary interventionBinary angiographic restenosisAngiographic restenosis rateTarget lesion revascularizationReference vessel diameterComplex coronary lesionsMinimal lumen diameterStudy of patientsPercent diameter stenosisVessel diameterTreatment effectsBeta-Cath SystemBreslow-Day testLesion revascularizationAngiographic restenosis